Changes in the Management Board of Eckert & Ziegler

Berlin, 19.12.2022. The founder and CEO of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), Dr. Andreas Eckert, today gave notice to the company that he intends to transfer from the Management to the Supervisory Board after the company’s General Shareholder Meeting in mid-2023. Before that the Supervisory Board appointed, for a period of two years effective 01 January 2023, two additional new Executive Directors, Dr. Hakim Bouterfa as Chief Medical Officer and Jutta Ludwig as Head of Asia. Both are already with the Eckert & Ziegler and shall now, albeit on the Board level, support Dr. Harald Hasselmann, whom Eckert recommended as his successor.

Triggering the restructuring was the recent endorsement of the European Medicine Agency of Eckert & Ziegler’s phase III registration study. It necessitated an adjustment of senior management assignments and opened an opportunity to pass on responsibility to a new group of executives. Eckert, who heads the group now for more than 30 years, is one of the longest serving CEOs among German listed companies and wants to withdraw from operational activities.

Eckert Wagniskapital und Frühphasenfinanzierung GmbH, who holds more than 30% of the shares of Eckert & Ziegler and the right to nominate members of the Supervisory Board, supports the transfer of Eckert, so that the change will be in line with the regulations of the German Stock Corporation Act and the recommendations of the German Corporate Governance Code.

For enquiries please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com